|
|
Article: Efficacy trials completed for treatment of African sleeping sickness.
- Article from:
- Biotech Week
- Article date:
- December 25, 2002
CopyrightCOPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2002 DEC 25 - (NewsRx.com & NewsRx.net) -- Immtech International, Inc., (IMMT), a pharmaceutical company focused on the commercialization of oral treatments for fungal and other infectious diseases, announced the completion of the phase IIa human trials of its first compound, DB289, for the treatment of African sleeping sickness (trypanosomiasis).
Initial trial results showed that DB289 was well tolerated and approximately 95% of the patients treated were cured. Data for 5% of the patients was not confirmed due to civil war unrest in Angola. Trial participants were requested to attend a follow-up exam 3 months after the conclusion of their treatment; all the ...